Von Willebrand factor D'D3 domains (VWF-D'D3)

The Von Willebrand factor (VWF) D'D3 domains constitute the critical binding interface for Coagulation Factor VIII (FVIII), playing a vital role in maintaining FVIII stability and preventing its premature degradation in the plasma (UniProt P04275). In physiological conditions, the half-life of FVIII is tethered to that of endogenous VWF, creating a half-life ceiling for traditional replacement therapies. To overcome this, bioengineered fusion constructs like Efanesoctocog alfa (Altuviiio) incorporate the VWF D'D3 domains directly into the recombinant protein (FDA, 2023). This internal interface shields the FVIII molecule from endogenous VWF binding and clearance mechanisms, significantly extending its therapeutic duration in patients with Hemophilia A (NEJM, 2020). By mimicking the natural FVIII-VWF interaction within a single covalent structure, these constructs provide more stable and prolonged clotting factor activity. This approach represents a major advancement in the management of bleeding disorders by reducing the frequency of required infusions. The D'D3 domain specifically encompasses the amino-terminal region of VWF, which is essential for high-affinity binding to the FVIII light chain. Therapeutic utilization of this interface is a key strategy in protein engineering to improve the pharmacokinetics of clotting factors.

Other names

VWF D'D3 regionFactor VIII binding domain of VWFD'D3 domainVWF-FVIII binding interface

The D'D3 domains of Von Willebrand factor are incorporated into fusion proteins to stabilize Factor VIII and prevent its binding to endogenous Von Willebrand factor, thereby extending its circulatory half-life beyond the physiological limit.